PRX-102 for treating Fabry disease: immunogenicity and PK results from a phase 1-2 study

被引：2
作者：
Warnock, David [1 ]
Hughes, Derralynn [2 ]
Boyd, Simeon [3 ]
Giraldo, Pilar [4 ]
Gonzalez, Derlis [5 ]
Holida, Myrl [6 ]
Goker-Alpan, Ozlem [7 ]
Maegawa, Gustavo [8 ]
Atta, Mohamed [9 ]
Nicholls, Kathy [10 ,11 ]
Schiffmann, Raphael [12 ]
Tuffaha, Ahmad [13 ]
Charney, Martha
Chertkoff, Raul [14 ]
Alon, Sari [15 ]
Brill-Almon, Einat [15 ]
机构：
[1] UAB, Birmingham, AL USA
[2] UCL, London, England
[3] UC Davis Med Ctr, Sacramento, CA USA
[4] Hosp Dia Quiron, Zaragoza, Spain
[5] Inst Privado Hematol Invest Clin, Asuncion, Paraguay
[6] Univ Iowa, Iowa City, IA USA
[7] O&O Alpan LLC, Fairfax, VA USA
[8] Univ Florida, Gainesville, FL USA
[9] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[10] Royal Melbourne Hosp, Melbourne, Vic, Australia
[11] Univ Melbourne, Parkville, Vic, Australia
[12] Baylor Univ, Dallas, TX USA
[13] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[14] Protalix, Carmiel, AL USA
[15] Protalix, Carmiel, Israel
来源：
MOLECULAR GENETICS AND METABOLISM | 2017年 / 120卷 / 1-2期
关键词：
D O I：
10.1016/j.ymgme.2016.11.364
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
355
引用
收藏
页码：S137 / S138
页数：2
相关论文
共 50 条
  • [21] Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
    Faderl, S
    Gandhi, V
    O'Brien, S
    Bonate, P
    Cortes, J
    Estey, E
    Beran, M
    Wierda, W
    Garcia-Manero, G
    Ferrajoli, A
    Estrov, Z
    Giles, FJ
    Du, M
    Kwari, M
    Keating, M
    Plunkett, W
    Kantarjian, H
    [J]. BLOOD, 2005, 105 (03) : 940 - 947
  • [22] A randomized, double-blind study on the safety and immunogenicity of rTSST-1 variant vaccine: phase 2 results
    Schoergenhofer, Christian
    Gelbenegger, Georg
    Hasanacevic, Dzenita
    Schoener, Lea
    Steiner, Margarete M.
    Firbas, Christa
    Buchtele, Nina
    Derhaschnig, Ulla
    Tanzmann, Andreas
    Model, Nina
    Larcher-Senn, Julian
    Drost, Manuel
    Eibl, Martha M.
    Roetzer, Andreas
    Jilma, Bernd
    [J]. ECLINICALMEDICINE, 2024, 67
  • [23] Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study
    Wanner, Christoph
    Kimonis, Virginia
    Politei, Juan
    Warnock, David G.
    Ueceyler, Nurcan
    Frey, Aline
    Cornelisse, Peter
    Hughes, Derralyn
    [J]. MOLECULAR GENETICS AND METABOLISM REPORTS, 2022, 31
  • [24] Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study - determination of immunogenicity
    Warnock, David G.
    Wallace, Eric L.
    [J]. JOURNAL OF MEDICAL GENETICS, 2024, 61 (06) : 534 - 535
  • [25] Pegunigalsidase alfa for the treatment of Fabry disease: Preliminary results from a phase III open label, switch over study from agalsidase alfa
    Linhart, Ales
    Nicholls, Kathy
    West, Michael
    Tondel, Camilla
    Jovanovic, Ana
    Giraldo, Pilar
    Vujkovac, Bojan
    Almon, Einat
    Alon, Sari
    Amit-Cohen, Bat-chen
    Szlaifer, Mali
    Chertkoff, Raul
    Hughes, Derralynn
    [J]. MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S94 - S94
  • [26] Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study-determination of immunogenicity
    Lenders, Malte
    Brand, Eva
    [J]. JOURNAL OF MEDICAL GENETICS, 2024, 61 (06) : 531 - 533
  • [27] Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomas: Final Results from a Phase 1-2 Trial
    Abramson, Jeremy S.
    Jacobsen, Eric D.
    Redd, Robert Allyn
    Takvorian, Tak
    Fisher, David C.
    Brown, Jennifer R.
    Schwartz, Joel H.
    Weitzman, James
    Neuberg, Donna
    Barnes, Jeffrey A.
    Hochberg, Ephraim P.
    [J]. BLOOD, 2014, 124 (21)
  • [28] Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the phase 3 RECOURSE trial.
    Cleary, James M.
    Mayer, Robert J.
    Van Cutsem, Eric
    Yamashita, Fumiaki
    Yoshisue, Kunihiro
    Ieiri, Ichiro
    Ohtsu, Atsushi
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] PHARMACOKINETICS (PK), SAFETY, AND EFFICACY OF INTRAVENOUS (IV) VEDOLIZUMAB IN PEDIATRIC PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE: RESULTS FROM THE PHASE 2 HUBBLE STUDY
    Hyams, Jeffrey S.
    Turner, Dan
    Cohen, Stanley A.
    Szakos, Erzsebet
    Kowalska-Duplaga, Kinga
    Ruemmele, Frank
    Croft, Nicholas M.
    Korczowski, Bartosz
    Lawrence, Promise
    Bhatia, Siddharth
    Kadali, Harisha
    Chen, Chunlin
    Sun, Wan
    Rosario, Maria
    Suri, Ajit
    Gulati, Parul
    Treem, William
    Rossiter, Guillermo
    Lirio, Richard A.
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S716 - S716
  • [30] POPULATION PHARM ACOKINETICS (PK) AND PK/PHARMACODYN AMICS ANALYSES TO REFINE PHASE 3 DOSE OF SETRUSUMAB IN PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA: RESULTS FROM PHASE 2 OF THE ORBIT STUDY
    Tai, H.
    Wang, G.
    Wang, H.
    Hawtin, R.
    Byers, H.
    Krolczyk, S.
    Peng, E.
    Lee, S.
    Imel, E.
    Carpenter, T.
    Gottesman, G.
    Putnam, W.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S109 - S109
12345